Abstract
The antinociceptive properties of cannabinoids in persistent pain are not fully elucidated. We investigated the effect of repeated treatment with the synthetic cannabinoid receptor agonist WIN 55,212-2 on the neuropathic pain induced in rats by chronic constriction of the sciatic nerve. WIN 55,212-2 administered daily throughout the development of neuropathy reversed the hyperalgesia, at a dose (0.1 mg kg -1, s.c.) that had no effect on the nociceptive responses of either paw contralateral to the sciatic ligation or of animals subjected to sham surgery. At 14 days after injury, the levels of mediators known to be involved in neuropathic pain, such as prostaglandin E2, NO and the neuronal NOS, were increased. Repeated treatment with WIN 55,212-2 abolished these increases. In the light of the current clinical need for neuropathic pain treatments, these findings indicate that cannabinoid agonists, at doses devoid of psychoactive effects, could constitute important compounds for the development of new analgesics.
| Original language | English |
|---|---|
| Pages (from-to) | 4-8 |
| Number of pages | 5 |
| Journal | British Journal of Pharmacology |
| Volume | 141 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2004 |
Fingerprint
Keywords
- Endogenous cannabinoid system
- Neuropathic pain
- Nitric oxide system
- WIN 55,212-2
ASJC Scopus subject areas
- Pharmacology
Cite this
Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. / Costa, B.; Colleoni, M.; Conti, S.; Trovato, A. E.; Bianchi, M.; Sotgiu, M. L.; Giagnoni, G.
In: British Journal of Pharmacology, Vol. 141, No. 1, 01.2004, p. 4-8.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain
AU - Costa, B.
AU - Colleoni, M.
AU - Conti, S.
AU - Trovato, A. E.
AU - Bianchi, M.
AU - Sotgiu, M. L.
AU - Giagnoni, G.
PY - 2004/1
Y1 - 2004/1
N2 - The antinociceptive properties of cannabinoids in persistent pain are not fully elucidated. We investigated the effect of repeated treatment with the synthetic cannabinoid receptor agonist WIN 55,212-2 on the neuropathic pain induced in rats by chronic constriction of the sciatic nerve. WIN 55,212-2 administered daily throughout the development of neuropathy reversed the hyperalgesia, at a dose (0.1 mg kg -1, s.c.) that had no effect on the nociceptive responses of either paw contralateral to the sciatic ligation or of animals subjected to sham surgery. At 14 days after injury, the levels of mediators known to be involved in neuropathic pain, such as prostaglandin E2, NO and the neuronal NOS, were increased. Repeated treatment with WIN 55,212-2 abolished these increases. In the light of the current clinical need for neuropathic pain treatments, these findings indicate that cannabinoid agonists, at doses devoid of psychoactive effects, could constitute important compounds for the development of new analgesics.
AB - The antinociceptive properties of cannabinoids in persistent pain are not fully elucidated. We investigated the effect of repeated treatment with the synthetic cannabinoid receptor agonist WIN 55,212-2 on the neuropathic pain induced in rats by chronic constriction of the sciatic nerve. WIN 55,212-2 administered daily throughout the development of neuropathy reversed the hyperalgesia, at a dose (0.1 mg kg -1, s.c.) that had no effect on the nociceptive responses of either paw contralateral to the sciatic ligation or of animals subjected to sham surgery. At 14 days after injury, the levels of mediators known to be involved in neuropathic pain, such as prostaglandin E2, NO and the neuronal NOS, were increased. Repeated treatment with WIN 55,212-2 abolished these increases. In the light of the current clinical need for neuropathic pain treatments, these findings indicate that cannabinoid agonists, at doses devoid of psychoactive effects, could constitute important compounds for the development of new analgesics.
KW - Endogenous cannabinoid system
KW - Neuropathic pain
KW - Nitric oxide system
KW - WIN 55,212-2
UR - http://www.scopus.com/inward/record.url?scp=1242296234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1242296234&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0705587
DO - 10.1038/sj.bjp.0705587
M3 - Article
C2 - 14662732
AN - SCOPUS:1242296234
VL - 141
SP - 4
EP - 8
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
SN - 0007-1188
IS - 1
ER -